0K16.L
Evolus, Inc. [0K16.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0K16.L Stock Summary
In the News
0K16.L Financial details
Company Rating
-
Market Cap
747.81M
Income
-61.69M
Revenue
202.09M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
273
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-9.56
Forward P/E
-
PEG
5.3
P/S
3.41
P/B
-31.1
P/C
-
P/FCF
-14.1
Quick Ratio
1.42
Current Ratio
1.9
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.09
EPS next Y
-
EPS next Q
-
EPS this Y
-18.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.48%
Revenue last 5Y
42.06%
Revenue Q/Q
21.95%
EPS Q/Q
-30%
-
-
-
-
SMA20
27.82%
SMA50
-10.91%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-38%
ROE
28547%
ROC
-0.33%
Gross Margin
70%
Oper. Margin
-22%
Profit Margin
-34%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.121-15.38
52W High
-4.6%
52W Low
+104.43%
RSI
63.5
Rel Volume
0.04
Avg Volume
1.39K
Volume
52
Perf Week
0.42%
Perf Month
10.67%
Perf Quarter
-
Perf Half Y
-14.67%
-
-
-
-
Beta
1.45
-
-
Volatility
0.26%, 1.65%
Prev Close
1.06%
Price
14.31
Change
-0.83%
Company Profile
- Volume Average 1.39K
- Market Capitalization 747.81M
- Employee 273
- CEO Mr. David Moatazedi
- Headquarters Newport Beach,CA,US
- IPO Date 2018-08-03
-
Website
https://www.evolus.com 
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
